Siemens Healthineers has announced that it was selected by Quest Diagnostics, provider of diagnostic information services, to be its preferred supplier for immunoassay testing.

As part of the multi-year agreement, which builds on an existing partnership, upon successful execution of sequenced phases, the partnership foresees Quest Diagnostics deploying up to 120 Atellica Solution immunoassay analyzers across 19 esoteric and core laboratories throughout the U.S.

Additionally, a highly automated Quest lab in Clifton, New Jersey will feature Atellica Solution immunoassay analyzers connected to an Inpeco FlexLabTM automation system for a high-throughput, multidisciplinary testing solution designed to substantially increase productivity, reduce turnaround time, decrease unwanted variations, and lower operational costs. The new flagship lab is expected to be completed in 2021.

Deepak Nath, President of Laboratory Diagnostics at Siemens Healthineers said, “Siemens Healthineers offers a comprehensive and quality in vitro diagnostics portfolio that is proving to be attractive to leading laboratory providers across the globe. Our leadership in workflow and automation is resonating with laboratories worldwide and driving adoption of the Atellica Solution. The breadth and depth of our testing solutions—a highly scalable and flexible offering with the Atellica Solution, and a broad immunoassay test menu with proven assay performance, will provide the clinical outcomes Quest Diagnostics requires.”

Jim Davis, Executive Vice President, General Diagnostics of Quest Diagnostics said, “Our strategic relationship with Siemens Healthineers led to the development of a flexible solution that will improve our existing workflow and help us achieve greater cost savings. We look forward to implementing this solution throughout our laboratory network.”

The Atellica Solution offers a flexible solution and quality clinical capabilities required to serve Quest’s providers and patients. Leveraging the features and broad assay menu the Atellica Solution offers, Quest will be able to increase its immunoassay testing volume and improve turnaround time concurrently.